PURPOSE: While vascularized lymph node transplant (VLNT) has gained popularity, there are a lack of prospective long-term studies and standardized outcomes. The purpose of this study was to evaluate the safety and efficacy of VLNT using all available outcome measures. METHODS: This was a prospective study on all consecutive patients who underwent VLNT. Outcomes were assessed with 2 patient-reported outcome metrics, limb volume, bioimpedance, need for compression, and incidence of cellulitis. RESULTS: There were 89 patients with the following donor sites: omentum (73%), axilla (13%), supraclavicular (7%), groin (3.5%). The mean follow-up was 23.7±12 months. There was a significant improvement at 2 years postoperatively across all outcome measures: 28.4% improvement in the Lymphedema Life Impact Scale, 20% average reduction in limb volume, 27.5% improvement in bioimpedance score, 93% reduction in cellulitis, and 34% of patients no longer required compression. Complications were transient and low without any donor site lymphedema. CONCLUSIONS: VLNT is a safe and effective treatment for lymphedema with significant benefits fully manifesting at 2 years postoperatively. Omentum does not have any donor site lymphedema risk making it an attractive first choice.
PURPOSE: While vascularized lymph node transplant (VLNT) has gained popularity, there are a lack of prospective long-term studies and standardized outcomes. The purpose of this study was to evaluate the safety and efficacy of VLNT using all available outcome measures. METHODS: This was a prospective study on all consecutive patients who underwent VLNT. Outcomes were assessed with 2 patient-reported outcome metrics, limb volume, bioimpedance, need for compression, and incidence of cellulitis. RESULTS: There were 89 patients with the following donor sites: omentum (73%), axilla (13%), supraclavicular (7%), groin (3.5%). The mean follow-up was 23.7±12 months. There was a significant improvement at 2 years postoperatively across all outcome measures: 28.4% improvement in the Lymphedema Life Impact Scale, 20% average reduction in limb volume, 27.5% improvement in bioimpedance score, 93% reduction in cellulitis, and 34% of patients no longer required compression. Complications were transient and low without any donor site lymphedema. CONCLUSIONS: VLNT is a safe and effective treatment for lymphedema with significant benefits fully manifesting at 2 years postoperatively. Omentum does not have any donor site lymphedema risk making it an attractive first choice.
Authors: Elizabeth O Kenworthy; Jonas A Nelson; Richa Verma; JeanJacques Mbabuike; Babak J Mehrara; Joseph H Dayan Journal: J Surg Oncol Date: 2018-03-08 Impact factor: 3.454
Authors: Anne M Saaristo; Tarja S Niemi; Tiina P Viitanen; Tomi V Tervala; Pauliina Hartiala; Erkki A Suominen Journal: Ann Surg Date: 2012-03 Impact factor: 12.969
Authors: Alberto Bolletta; Giuseppe di Taranto; Luigi Losco; Rossella Elia; Gokhan Sert; Diego Ribuffo; Emanuele Cigna; Hung-Chi Chen Journal: Microsurgery Date: 2022-01-07 Impact factor: 2.425
Authors: Edward I Chang; Amir Ibrahim; Jun Liu; Charee Robe; Hiroo Suami; Matthew M Hanasono; Alexander T Nguyen Journal: Plast Reconstr Surg Date: 2020-04 Impact factor: 4.730